RBC Capital's Jason Kantor weighs in on the news that Seattle Genetics (SGEN -0.3%) scored a...


RBC Capital's Jason Kantor weighs in on the news that Seattle Genetics (SGEN -0.3%) scored a victory with testing of its Adcetris drug for Hodgkin lymphoma, and is closing in on Phase III trials. The analysts say that if the drug becomes part of first-line treatment, it would "significantly increase" the target population for it by 4X-5X. "Most doctors we talk to believe Adcetris will ultimately become part of standard of care."
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs